Continuous Renal Replacement Therapy Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is the Continuous Renal Replacement Therapy Market in 2026?

USD 1.6 billion in 2026, reaching USD 3.5 billion by 2036 at an 8.1% CAGR

The continuous renal replacement therapy market is estimated at USD 1.6 billion in 2026 and is forecast to reach USD 3.5 billion by 2036 at an 8.1% CAGR. Demand is shaped by rising acute kidney injury caseloads in intensive care units, where clinicians need slow, continuous fluid removal for hemodynamically unstable patients. Consumables account for 53.0% of product demand in 2026, while Renal therapy holds 70.0% share.

The market was valued at USD 1.4 billion in 2025. Growth reflects expanding critical-care capacity across hospital ICUs and a widening installed base of standalone CRRT systems that pull recurring filter, tubing, and replacement-fluid revenue. Adoption is increasing due to protocols favoring continuous therapy over intermittent dialysis for septic and post-surgical patients who cannot tolerate rapid volume shifts.

Continuous renal replacement therapy is shifting from selective ICU use to a standing modality for unstable acute kidney injury patients. Buyers judge systems through consumable cost per treatment day and filter life. 

Summary of the Continuous Renal Replacement Therapy Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Demand follows hospital critical-care activity, where ICUs treating acute kidney injury generate recurring, per-treatment consumption of filters, tubing, and replacement fluids. Hospital intensive care units adopt continuous venovenous hemofiltration to manage acute kidney injury in septic and post-surgical patients who cannot tolerate intermittent dialysis. Critical-care expansion lifts recurring demand for hemofilters, tubing sets, and bicarbonate-based replacement fluids tied to each treatment day. Adult patient caseloads in teaching and multi-specialty hospitals drive standardization on standalone CRRT systems with predictable consumable contracts.
Product and Segment View	Consumables and renal therapy dominate the mix, with continuous venovenous hemofiltration the leading modality. Consumables account for 53.0% of Product Type demand, anchored by hemofilters, tubing sets, and dialysate and replacement fluids consumed per treatment. Renal therapy holds 70.0% share as kidney-indication caseloads outweigh non-renal and combination uses. Continuous Venovenous Hemofiltration leads Modality at 34.0% share due to its convective clearance profile in fluid-overloaded patients.
Geography and Competitive Outlook	Growth is fastest in markets expanding ICU capacity such as China, while established device makers compete on integrated systems and consumable ecosystems. China is forecast to record 8.1% CAGR by 2036 due to government hospital expansion and rising ICU bed capacity. India and Germany follow at 7.6% and 7.2% CAGR as private critical-care investment and EU device standards shape sourcing. Fresenius Medical Care and Baxter compete with B. Braun through systems plus consumable ecosystems. Filter performance and service coverage separate suppliers.
Analyst Opinion	Competitive advantage will rest on the economics of continuous therapy rather than on system placement alone. Suppliers that lower consumable cost per treatment day and extend filter life across longer therapy sessions will hold the strongest position in hospital critical-care procurement. Adoption is increasing due to ICU protocols that select continuous therapy for hemodynamically unstable patients over intermittent alternatives. - Anurag Sharma, Principal Consultant at Future Market Insights

Why is the Continuous Renal Replacement Therapy Market growing?

Rising Consumables and Renal therapy demand in hospital intensive care units

• Sustained procurement of hemofilters and replacement fluids is shaped by hospitals treating acute kidney injury in critically ill patients across ICU settings.
• China is leading the way with growth of 8.1%, driven by government hospital expansion, rising ICU bed capacity, and domestic manufacturing of CRRT consumables.
• The therapy segment is led by Renal at 70.0% share, supported by kidney-indication caseloads in acute kidney injury, sepsis management, and fluid overload management.

Demand is rising because intensive care units need continuous, gentle fluid and solute removal for patients who cannot tolerate intermittent hemodialysis. Adoption is increasing due to the consumable-intensive nature of therapy, where each treatment day consumes hemofilters, tubing sets, and bicarbonate-based or lactate-based replacement fluids, tying market value directly to ICU caseload and therapy duration.

How is the Continuous Renal Replacement Therapy Market segmented?

By Product Type, Therapy, Modality, End User, Patient Type and Application

• Consumables are projected to lead Product Type demand with 53.0% share in 2026 because each treatment day consumes filters, tubing, and fluids.
• Renal therapy is expected to lead with 70.0% share in 2026 as kidney-indication caseloads outweigh non-renal uses.
• Hospitals are forecast to lead End User with 80.0% share in 2026 as critical-care delivery concentrates in inpatient settings.

Why do Consumables lead the Continuous Renal Replacement Therapy Market?

• Consumables are expected to hold 53.0% share in 2026 because hemofilters, tubing sets, and replacement fluids are consumed per treatment day rather than purchased once.
• High-flux and low-flux filters and bicarbonate-based fluids generate recurring revenue tied to therapy duration and ICU caseload.

Renal therapy holds 70.0% share, led by acute kidney injury indications

• Renal therapy forms the leading block at 70.0% share, anchored by acute kidney injury and fluid overload management indications.
• Non-renal and combination therapy uses such as sepsis management remain secondary but expand the clinical addressable base.

Which Modality leads the market?

• Continuous Venovenous Hemofiltration is estimated to represent 34.0% Modality share in 2026 due to its convective solute clearance.
• Continuous venovenous hemodialysis and hemodiafiltration follow where diffusion or combined clearance suits the patient profile.

Which End User leads sourcing?

• Hospitals are forecast to hold 80.0% End User share in 2026, with public, teaching, and multi-specialty hospitals running most CRRT caseloads.
• Ambulatory centers and specialty clinics follow as continuous therapy extends into transplant and cardiac surgery units.

Which Patient Type leads the market?

• Adult patients lead demand as acute kidney injury and critical illness concentrate in adult ICU populations.
• Pediatric and geriatric patient segments follow, with neonatal and age-related kidney failure cases requiring tailored circuit configurations.

What drives and restrains the Continuous Renal Replacement Therapy Market?

Driven by ICU acute kidney injury caseloads and consumable recurrence; restrained by procedure cost and specialist staffing

Critical-care caseloads and per-treatment consumable use support adoption, while high procedure cost and the need for trained ICU nephrology staff limit access in lower-resource settings.

• Driver: Hospital ICUs treating acute kidney injury in septic and post-surgical patients generate recurring demand for hemofilters, tubing sets, and replacement fluids tied to each therapy day.
• Restraint: Public hospitals delay CRRT scale-up when high consumable cost per treatment day and the need for trained critical-care nurses strain critical-care budgets.
• Opportunity: Portable and integrated CRRT systems can widen adoption by extending continuous therapy into cardiac surgery centers and transplant units beyond general ICUs.

Critical-care expansion is lifting demand for CRRT as hospitals manage more hemodynamically unstable acute kidney injury patients. Standalone and integrated CRRT systems anchor the installed base while hemofilters, tubing, and bicarbonate-based fluids generate recurring revenue per treatment day.

The market is led by structural demand from hospital intensive care units. Renal indications remain the leading therapy block, while non-renal uses such as sepsis management broaden the clinical base. Constraints include procedure cost, reimbursement variability, and the supply of trained critical-care staff.

Which factors support expansion in the Continuous Renal Replacement Therapy Market?

System placement and recurring consumable contracts support market value across hospital critical-care channels

• Market value is supported by standalone and integrated system placement before consumable contracts add recurring per-treatment revenue.
• Supplier pricing reflects filter clearance efficiency and fluid quality before service coverage affects renewal demand.
• Hospitals compare consumable cost per treatment day and filter life before standardizing on a CRRT platform.

Which countries are growing fastest in the Continuous Renal Replacement Therapy Market?

Country	CAGR
China	8.1%
India	7.6%
Germany	7.2%
Brazil	6.8%
USA	6.1%

Source: Future Market Insights analysis, 2026.

How do country-level CAGRs compare in the Continuous Renal Replacement Therapy Market?

Country growth in continuous renal replacement therapy should be read through the pace of critical-care capacity building. In the United States and Germany, demand reflects a mature ICU base where replacement is driven by consumables and regulated device standards. In China, India, and Brazil, the same category tracks fast ICU expansion and widening public access to critical care. For senior buyers, the question is where CRRT consumable reliability creates the most value in caseload growth and supplier qualification.

• China is estimated to record 8.1% CAGR through 2036 as government hospital expansion and ICU bed growth lift continuous venovenous hemofiltration caseloads. China's National Health Commission set a target of 15 intensive-care beds per 100,000 people by the end of 2025, up from about 5.31 per 100,000 in 2022, enlarging the installed base that drives CRRT consumable demand.
• India is expected to expand at 7.6% CAGR through 2036 as private critical-care investment and Ayushman Bharat coverage widen access to intensive care. Under the PM Ayushman Bharat Health Infrastructure Mission, critical-care hospital blocks are being funded across 602 districts, and 32,574 hospitals were empanelled under AB PM-JAY as of December 2025, broadening the base of ICUs that use replacement fluids and hemofilters.
• Germany is estimated to grow at 7.2% CAGR through 2036 as EU device standards and tertiary critical-care capacity shape procurement. Germany runs the largest hospital sector in the EU at about 7.9 beds per 1,000 people, with the DIVI intensive-care register tracking capacity across roughly 1,300 hospitals, sustaining steady demand for CRRT consumables.
• Brazil is projected to rise at 6.8% CAGR through 2036 as SUS public hospital networks expand critical-care services. The SUS 'Health in Our Hands' program cut ICU infections by 26% between September 2024 and October 2025, and the Ministry of Health is rolling out a national smart-hospital network with 14 smart ICUs from 2026, both reinforcing continued CRRT uptake.
• The United States is forecast to post 6.1% CAGR through 2036 as a mature ICU installed base shifts toward consumable-driven replacement. High-income health systems such as the United States report ICU bed densities of roughly 12 to 30 per 100,000 people, so growth is anchored in recurring hemofilter and replacement-fluid purchasing rather than new system placement.

Who are the leading companies in the Continuous Renal Replacement Therapy Market?

Fresenius Medical Care, Vantive, B. Braun Melsungen, Nikkiso, and Asahi Kasei

Fresenius Medical Care and Vantive compete through combined systems and consumable ecosystems. Filter performance is a further point of differentiation. B. Braun Melsungen and Nikkiso compete on hemofilter clearance and circuit design, while Asahi Kasei and Toray Medical hold positions in membrane technology. These overlap with broader dialysis and blood-purification buying paths.

Buyers compare suppliers on consumable cost per treatment day, filter life, and service coverage. Hospitals standardize on platforms that lower per-treatment cost and reduce circuit changes. Larger academic centers favor systems with validated clearance across continuous venovenous modalities and reliable replacement-fluid supply.

Who are the key players in the Continuous Renal Replacement Therapy Market?

Key global companies include:

• Fresenius Medical Care, Vantive, and B. Braun Melsuingen maintain leading positions through systems, consumable portfolios, and direct hospital relationships across global markets.
• Membrane and circuit specialists such as Nikkiso, Asahi Kasei, Toray Medical, and Nipro compete through filter clearance efficiency and consumable supply.
• Specialist and emerging providers such as Cytosorbents and Medica target blood-purification and adsorption niches to establish clinical positions and scale.

How do top Continuous Renal Replacement Therapy Market companies compare?

Fresenius and Baxter lead on scale; B. Braun also has a global footprint, while Nikkiso and Asahi Kasei are more membrane-concentrated.

Company	Product Breadth	Consumable Depth	Deployment Scale	Geographic Footprint
Fresenius Medical Care	High	High	Strong	Global
Vantive	High	High	Strong	Global
B. Braun Melsungen	High	Moderate	Strong	Europe-led
Nikkiso	Moderate	High	Moderate	Asia-led
Asahi Kasei	Moderate	High	Moderate	Asia-led
Cytosorbents	Moderate	Moderate	Moderate	Americas-led

Source: Future Market Insights competitive analysis, 2026.

Key Developments in the Continuous Renal Replacement Therapy Market

• In August 2024, Baxter International signed a definitive agreement to divest its Kidney Care segment, renamed Vantive, to Carlyle for USD 3.8 billion, with the transaction completing in January 2025. Separation of the PrisMax and Prismaflex CRRT franchise into a standalone, capital-backed entity reshapes ownership of a leading acute platform and supports hospital buyers assessing long-term supply continuity for CRRT devices and consumables. 

• In June 2025, Vantive announced a plan to invest more than USD 1 billion over five years across research and development and production capacity, alongside digitally enabled CRRT management through the PrisMax System with embedded TrueVue Connect. Committed manufacturing and digital investment supports ICU purchasers needing assurance of consumables supply reliability and connectivity readiness before platform standardisation decisions. 

• In December 2025, SeaStar Medical received FDA approval for a reduction in mandatory enrolment for the SAVE Surveillance Registry, the post-approval study supporting QUELIMMUNE, an immunomodulatory device integrated in-line with existing CRRT circuits for pediatric acute kidney injury due to sepsis. Lower registry participation requirements reduce the institutional onboarding burden and support pediatric intensive care units evaluating CRRT-integrated adjunct therapy before adoption. 

Key Players in the Continuous Renal Replacement Therapy Market

Global Device Leaders

• Fresenius Medical Care AG.
• Vantive
• B. Braun Melsungen AG

Membrane and Consumable Specialists

• Nikkiso Co., Ltd.
• Toray Medical Co., Ltd.
• Asahi Kasei Corporation
• Nipro Corporation

Emerging and Niche Players

• Cytosorbents Corporation
• Medica S.p.A.
• Infomed SA

Continuous Renal Replacement Therapy Market - Scope & Definition

Attribute	Detail
Market Definition	Continuous extracorporeal blood-purification therapy and associated systems, consumables, and fluids used to manage acute kidney injury and fluid overload in critically ill patients
Functions Covered	Continuous fluid removal, solute clearance, electrolyte balance, and blood purification across continuous venovenous modalities
Applications Covered	Acute kidney injury, fluid overload management, sepsis management, electrolyte imbalance, and ICU-related kidney failure
End-Use Industries	Hospitals, ambulatory centers, specialty clinics, and dialysis centers
Inclusions	CRRT systems, hemofilters, tubing sets, dialysate and replacement fluids, catheters, and collection systems
Exclusions	Chronic intermittent hemodialysis equipment, standalone peritoneal dialysis, and consumables outside continuous therapy circuits

Continuous Renal Replacement Therapy Market - Research Methodology

Method	Description
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, sourcing teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing & Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

What does the Continuous Renal Replacement Therapy Market report cover?

2021 to 2025 history and 2026 to 2036 forecasts across all segments and 30+ countries

Parameter	Details
Forecast period	2026 to 2036
Historical period	2021 to 2025
Quantitative unit	Value in USD billion
By Product type	Consumables, Systems, Dialysate and Replacement Fluids, Accessories
By Therapy	Renal, Non-Renal, Combination
By Modality	Continuous Venovenous Hemofiltration, Continuous Venovenous Hemodialysis, Continuous Venovenous Hemodiafiltration, Slow Continuous Ultrafiltration
By End user	Hospitals, Ambulatory Centers, Specialty Clinics, Dialysis Centers
By Patient type	Adult Patients, Pediatric Patients, Geriatric Patients
By Application	Acute Kidney Injury, Fluid Overload Management, Sepsis Management, Electrolyte Imbalance
Regions Covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	USA, China, India, Germany, Brazil, and other major markets
Key companies profiled	Fresenius Medical Care, Vantive, B. Braun Melsungen, Nikkiso, Toray Medical, Asahi Kasei, Nipro, Cytosorbents
Approach	Bottom-up clinical-use approach using system placement, consumable use per treatment, ICU caseload, and supplier disclosures

Market Segmentation Analysis

Continuous Renal Replacement Therapy Market Segmented by Product Type:

• Consumables
  • Hemofilters
    • High Flux Filters
    • Low Flux Filters
  • Tubing Sets
    • Standard Tubing Kits
    • Customized Tubing Sets
  • Dialysate and Replacement Fluids
    • Bicarbonate Based Fluids
    • Lactate Based Fluids
• Systems
  • Standalone CRRT Systems
    • Bedside CRRT Machines
    • Portable CRRT Systems
  • Integrated CRRT Systems
    • Multi Therapy Platforms
    • ICU Integrated Systems
• Dialysate & Replacement Fluids
• Accessories
  • Catheters
    • Double Lumen Catheters
    • Temporary Catheters
  • Collection Systems
    • Waste Collection Bags
    • Fluid Management Systems

Continuous Renal Replacement Therapy Market Segmented by Therapy:

• Renal
• Non-Renal
• Combination

Continuous Renal Replacement Therapy Market Segmented by Modality:

• Continuous Venovenous Hemofiltration
  • Pre Dilution Method
    • Fluid Replacement Before Filter
    • Improved Filter Life
  • Post Dilution Method
    • Higher Clearance Efficiency
    • Enhanced Solute Removal
• Continuous Venovenous Hemodialysis
  • Diffusion Based Therapy
    • Small Molecule Clearance
    • Stable Electrolyte Balance
  • Low Flow Dialysis
    • Gentle Fluid Removal
    • Hemodynamic Stability
• Continuous Venovenous Hemodiafiltration
  • Combination Therapy
    • Diffusion and Convection
    • High Clearance Efficiency
  • High Volume Therapy
    • Intensive Care Applications
    • Severe Kidney Failure
• Slow Continuous Ultrafiltration (SCUF)

Continuous Renal Replacement Therapy Market Segmented by End User:

• Hospitals
  • Public Hospitals
    • Government ICUs
    • Teaching Hospitals
  • Private Hospitals
    • Multi Specialty Hospitals
    • Advanced Critical Care Units
• Ambulatory Centers
  • Outpatient Care Centers
    • Day Care Units
    • Short Stay Centers
  • Specialty Surgical Units
    • Cardiac Surgery Centers
    • Transplant Centers
• Specialty Clinics
• Dialysis Centers
  • Independent Dialysis Centers
    • Standalone Units
    • Chain Dialysis Networks
  • Hospital Based Dialysis Units
    • Inpatient Dialysis
    • Outpatient Dialysis

Continuous Renal Replacement Therapy Market Segmented by Patient Type:

• Adult Patients
  • Critical Care Patients
    • ICU Patients
    • Emergency Cases
  • Chronic Kidney Patients
    • Acute on Chronic Kidney Disease
    • Dialysis Dependent Patients
• Pediatric Patients
  • Neonatal Patients
    • NICU Care
    • Low Weight Infants
  • Children
    • Pediatric ICU Patients
    • Congenital Disorders
• Geriatric Patients
  • Elderly Patients
    • Age Related Kidney Failure
    • Comorbid Conditions
  • Long Term Care Patients
    • Chronic Illness Management
    • Post Operative Care

Continuous Renal Replacement Therapy Market Segmented by Application:

• Acute Kidney Injury
  • ICU Related Kidney Failure
  • Trauma Related AKI
• Fluid Overload Management
  • Cardiac Patients
  • Critical Care Patients
• Electrolyte Imbalance
  • Hyperkalemia Treatment
  • Acid Base Disorders
• Sepsis Management
  • Septic Shock Treatment
  • Toxin Removal

Continuous Renal Replacement Therapy Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Türkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• World Health Organization. (2025, October). Global report on kidney health and critical-care capacity.
• Organisation for Economic Co-operation and Development. (2025, November). Health at a Glance: intensive-care resources across member states.
• USA Food and Drug Administration. (2026, February 10). Device classification and clearances for continuous renal replacement systems.
• European Commission. (2025, December 9). Medical Device Regulation guidance for blood-purification devices.
• National Health Commission of China. (2025, September). Tertiary hospital critical-care capacity bulletin.
• Indian Council of Medical Research. (2026, January). Critical-care and acute kidney injury management guidance.
• Fresenius Medical Care AG. (2026, February 24). 2025 annual report and renal-care segment overview.
• Vantive 2025 results and acute therapies portfolio update.

This bibliography is provided for reader reference and is not exhaustive.

This Report Answers

• Market size estimates for 2026 and forecasts through 2036 for the Continuous Renal Replacement Therapy Market.
• Analysis of product demand across consumables and systems with dialysate and replacement fluids.
• Country-level growth analysis covering China and India with Germany, Brazil and USA outlooks.
• Evaluation of company positioning across Fresenius Medical Care and Baxter with B. Braun, Nikkiso and Asahi Kasei.
• Assessment of drivers and restraints with procurement patterns across hospital critical-care channels.